Eri Kato

12.6k total citations · 3 hit papers
47 papers, 7.5k citations indexed

About

Eri Kato is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Rheumatology. According to data from OpenAlex, Eri Kato has authored 47 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Endocrinology, Diabetes and Metabolism, 13 papers in Cardiology and Cardiovascular Medicine and 13 papers in Rheumatology. Recurrent topics in Eri Kato's work include Diabetes Treatment and Management (14 papers), Metabolism, Diabetes, and Cancer (6 papers) and Systemic Lupus Erythematosus Research (5 papers). Eri Kato is often cited by papers focused on Diabetes Treatment and Management (14 papers), Metabolism, Diabetes, and Cancer (6 papers) and Systemic Lupus Erythematosus Research (5 papers). Eri Kato collaborates with scholars based in Japan, United States and United Kingdom. Eri Kato's co-authors include Marc S. Sabatine, Darren K. McGuire, Marc P. Bonaca, Avivit Cahn, Ofri Mosenzon, Deepak L. Bhatt, John Wilding, Lawrence A. Leiter, Stephen D. Wiviott and Thomas A. Zelniker and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Eri Kato

44 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

2018 4.3k citations Stephen D. Wiviott, Itamar Raz et al. profile →
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

2018 1.9k citations Thomas A. Zelniker, Stephen D. Wiviott et al. The Lancet profile →
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus

2019 534 citations Thomas A. Zelniker, Stephen D. Wiviott et al. Circulation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eri Kato Japan	15	6.0k	2.5k	2.5k	2.0k	926	47	7.5k
Thomas A. Zelniker United States	21	6.8k 1.1×	2.8k 1.1×	2.8k 1.1×	2.5k 1.2×	1.3k 1.4×	68	8.8k
Wayne Shaw United States	24	7.0k 1.2×	3.0k 1.2×	2.7k 1.1×	1.9k 0.9×	986 1.1×	36	8.3k
Avivit Cahn Israel	29	7.7k 1.3×	3.0k 1.2×	3.1k 1.3×	2.0k 1.0×	1.1k 1.2×	113	9.3k
Michael G. Silverman United States	22	4.5k 0.7×	2.6k 1.1×	1.9k 0.8×	2.0k 1.0×	706 0.8×	44	6.8k
Mehul Desai United States	30	7.8k 1.3×	3.4k 1.4×	3.3k 1.3×	2.0k 1.0×	1.1k 1.2×	49	9.5k
Hans J. Woerle Germany	17	8.5k 1.4×	3.5k 1.4×	3.5k 1.4×	2.4k 1.2×	931 1.0×	26	10.0k
Itamar Raz United States	9	4.0k 0.7×	1.6k 0.6×	1.6k 0.7×	1.1k 0.6×	583 0.6×	9	4.7k
Matthew A. Cavender United States	28	4.7k 0.8×	2.1k 0.8×	2.0k 0.8×	2.3k 1.2×	370 0.4×	86	6.7k
KyungAh Im United States	24	3.5k 0.6×	1.5k 0.6×	1.4k 0.6×	1.5k 0.8×	446 0.5×	47	4.7k
Stefan Hantel Germany	27	9.4k 1.6×	4.7k 1.9×	4.0k 1.6×	4.9k 2.4×	1.2k 1.3×	63	13.8k

Countries citing papers authored by Eri Kato

Since Specialization

Citations

This map shows the geographic impact of Eri Kato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eri Kato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eri Kato more than expected).

Fields of papers citing papers by Eri Kato

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eri Kato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eri Kato. The network helps show where Eri Kato may publish in the future.

Co-authorship network of co-authors of Eri Kato

This figure shows the co-authorship network connecting the top 25 collaborators of Eri Kato. A scholar is included among the top collaborators of Eri Kato based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eri Kato. Eri Kato is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bauersachs, Johann, Eri Kato, & Janani Rangaswami. (2025). Interconnected Pathways and Emerging Therapies in Chronic Kidney Disease and Heart Failure: A Comprehensive Review. ESC Heart Failure. 12(5). 3226–3249. 1 indexed citations

Wada, Yuko, Kanae Hasegawa, Hai Huang, et al.. (2023). Non-missense variants ofKCNH2show better outcomes in type 2 long QT syndrome. EP Europace. 25(4). 1491–1499. 9 indexed citations

Kato, Eri, Koh Ono, & Basil S. Lewis. (2023). SGLT2 inhibitors in acute myocardial infarction: what can we learn from the DAPA-MI trial? More news from American Heart Association Scientific Meeting. European Heart Journal - Cardiovascular Pharmacotherapy. 10(2). 95–97. 2 indexed citations

Kato, Eri, Basil S. Lewis, & Koh Ono. (2023). GLP-1 receptor agonists: new game changing drugs in patients with heart failure with preserved ejection fraction and obesity. European Heart Journal - Cardiovascular Pharmacotherapy. 9(8). 679–680. 2 indexed citations

Kato, Eri & Junko Sato. (2023). Addressing health and demographic challenges in Japan's ageing society. The Lancet Diabetes & Endocrinology. 11(8). 543–544. 3 indexed citations

Kimura, Moritsugu, et al.. (2022). A Survey on the Current Status of Ophthalmological Consultations in Patients With Diabetes Undergoing Maintenance Hemodialysis and the Effectiveness of Education on Consultation Behavior –Experience of a Single Hemodialysis Clinic in Japan. SHILAP Revista de lepidopterología. 2. 827718–827718. 1 indexed citations

Kato, Eri, et al.. (2022). Nephrotic Syndrome as an Extramuscular Manifestation of Anti-EJ Antibody-Positive Dermatomyositis: A Case Report and Review of the Literature. SHILAP Revista de lepidopterología. 2022. 1–9.

Matsuo, Takashi, Ran Nakashima, Yoshihiro Kuwabara, et al.. (2022). ECG Changes Through Immunosuppressive Therapy Indicate Cardiac Abnormality in Anti-MDA5 Antibody-Positive Clinically Amyopathic Dermatomyositis. Frontiers in Immunology. 12. 765140–765140. 8 indexed citations

Suzuki, Shota, Eri Kato, Keiko Sato, et al.. (2021). The effect of the Original MethOd at pharmacy To ENhAnce Support for Health Improvement in the limited Japanese proficiency patients visiting local community pharmacy: A randomized controlled trial. Patient Education and Counseling. 105(2). 366–374. 3 indexed citations

10.

O’Donoghue, Michelle L., Eri Kato, Ofri Mosenzon, et al.. (2021). The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. Diabetologia. 64(6). 1226–1234. 17 indexed citations

11.

Kato, Eri, Sandeep R. Das, & Darren K. McGuire. (2020). Antihyperglycemic therapies and cardiovascular outcomes in patients with type 2 diabetes mellitus: State of the art and future directions. Trends in Cardiovascular Medicine. 31(2). 101–108. 8 indexed citations

12.

Takeji, Yasuaki, Hiroki Shiomi, Takeshi Morimoto, et al.. (2020). Diabetes Mellitus and Long-Term Risk for Heart Failure After Coronary Revascularization. Circulation Journal. 84(3). 471–478. 5 indexed citations

13.

Zelniker, Thomas A., Stephen D. Wiviott, Itamar Raz, et al.. (2019). Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 139(17). 2022–2031. 534 indexed citations breakdown →

14.

Mori, Hiroaki, Tetsuji Sawada, Susumu Nishiyama, et al.. (2019). Influence of seasonal changes on disease activity and distribution of affected joints in rheumatoid arthritis. BMC Musculoskeletal Disorders. 20(1). 30–30. 29 indexed citations

15.

Kishi, Takayuki, et al.. (2018). Vasodilatory Response to Knee Extension with Different Loads. Rigakuryoho Kagaku. 33(1). 1–5. 1 indexed citations

16.

Zelniker, Thomas A., Stephen D. Wiviott, Itamar Raz, et al.. (2018). SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet. 393(10166). 31–39. 1897 indexed citations breakdown →

17.

Wiviott, Stephen D., Itamar Raz, Marc P. Bonaca, et al.. (2018). The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial. American Heart Journal. 200. 83–89. 121 indexed citations

18.

Kato, Eri, et al.. (2017). Granulomatosis with Polyangiitis Complicated by Hypertrophic Pachymeningitis Presenting with Simultaneous Multiple Intracerebral Hemorrhages. Internal Medicine. 57(8). 1167–1172. 2 indexed citations

19.

Tamura, Noriko, et al.. (2017). A method and preliminary results of <i>in silico</i> computer simulation for the formation of mix thrombi with platelet and fibrin. 31(2). 30–34. 3 indexed citations

20.

Kato, Eri, Robert P. Giugliano, Christian T. Ruff, et al.. (2016). Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial. Journal of the American Heart Association. 5(5). 198 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact